<a href="https://laohu8.com/S/RNA">Avidity Biosciences</a> Announces $500 Million Public Offering of Common Stock to Advance Clinical Programs and Infrastructure Expansion
Avidity Biosciences Inc., a biopharmaceutical company focused on developing RNA therapeutics, has announced a proposed public offering of its common stock, aiming to raise $500 million. The offering will be underwritten, with the company granting underwriters a 30-day option to purchase up to an additional $75 million in shares. Proceeds from this offering will support the advancement of Avidity's late-stage clinical programs, commercial inventory development, infrastructure expansion, research on its AOC platform, and general corporate purposes. The offering is being handled by joint bookrunning managers including Leerink Partners, J.P. Morgan, TD Cowen, Cantor, and Wells Fargo Securities. A preliminary prospectus supplement related to the offering will be filed with the SEC.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA70729) on September 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.